While existing C5 inhibitors have contributed to improved remission rates, many patients still experience residual disease activity due to incomplete complement inhibition. In addition to ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

Now that Ultomiris has matched the indications of its predecessor Soliris, AstraZeneca is eyeing new avenues for the C5 drug ...

Late-stage pipeline products can generate demand in the MG market and with diagnosed prevalent cases, will drive growth in ...

Global Plasma Protease C1-Inhibitor Market is valued approximately USD 3752.3 million in 2023 and is anticipated to grow with a healthy growth rate of more than 17.72% over the forecast period ...

While existing C5 inhibitors have contributed to improved remission rates, many patients still experience residual disease activity due to incomplete complement inhibition. In addition to autoantibody ...

Dianthus Therapeutics focuses on developing DNTH103, a next-gen complement inhibitor for severe autoimmune diseases, currently in trials for CIDP, gMG, and MMN. Despite promising in vitro results ...

Doctors consider complement inhibitors a treatment option for C3G to slow down kidney damage. This type of medication stops complement system activity. A doctor may suggest these medications to ...

But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky. Q32 is persevering with bempikibart, an anti-IL-7R antibody that was unable to ...

DelveInsight’s 'Complement Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline complement inhibitors in various stages of clinical development ...

SAN DIEGO -- Intravenous ravulizumab (Ultomiris) yielded clinically meaningful reductions in IgA nephropathy-related proteinuria in a small, mid-stage trial. The 43 patients treated with ...